Predictive value of seizure ICD-9 codes for vaccine safety research

Vaccine

Volumn 27, Issue 39, 2009, Pages 5307-5312

  Shui, Irene M ^a   Shi, Ping ^a   Dutta Linn, M Maya ^a   Weintraub, Eric S ^b   Hambidge, Simon J ^c,d   Nordin, James D ^e   Lieu, Tracy A ^a,f  

^a HARVARD PILGRIM HEALTH CARE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c KAISER PERMANENTE   (United States)

^d Denver Health ^*  (United States)

^e HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Positive predictive value; Seizures; Vaccine safety

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; CHILD; CONVULSION; DRUG SAFETY; EMERGENCY WARD; EPILEPSY; GRAND MAL SEIZURE; HOSPITAL PATIENT; HUMAN; INFANT; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MANAGED CARE ORGANIZATION; MEDICAL RECORD; MEDICAL RESEARCH; MYOCLONUS; OUTPATIENT; PRIORITY JOURNAL; SEIZURE;

AMBULATORY CARE FACILITIES; EMERGENCY SERVICE, HOSPITAL; FEMALE; HUMANS; INFANT; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; PNEUMOCOCCAL VACCINES; PREDICTIVE VALUE OF TESTS; SEIZURES; VACCINATION;

EID: 68449099152     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.092     Document Type: Article

References (19)

1. Lieberman J.M., Williams W.R., Miller J.M., Black S., Shinefield H., Henderson F., et al. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Pediatr Infect Dis J 25 (2006) 615-622
2. Barlow W.E., Davis R.L., Glasser J.W., Rhodes P.H., Thompson R.S., Mullooly J.P., et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 345 (2001) 656-661
3. Stehr-Green P., Radke S., Kieft C., Galloway Y., McNicholas A., and Reid S. The risk of simple febrile seizures after immunisation with a new group B meningococcal vaccine, New Zealand. Vaccine 26 (2008) 739-742
4. Wise R.P., Iskander J., Pratt R.D., Campbell S., Ball R., Pless R.P., et al. Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine. JAMA 292 (2004) 1702-1710
5. Zangwill K.M., Eriksen E., Lee M., Lee J., Marcy S.M., Friedland L.R., et al. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization. Pediatrics 122 (2008) e1179-e1185
6. Goodman M.J., Nordin J.D., Harper P., Defor T., and Zhou X. The safety of trivalent influenza vaccine among healthy children 6 to 24 months of age. Pediatrics 117 (2006) e821-e826
7. Davis R.L., Marcuse E., Black S., Shinefield H., Givens B., Schwalbe J., et al. MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team. Pediatrics 100 (1997) 767-771
8. Mullooly J.P., Donahue J.G., Destefano F., Baggs J., and Eriksen E. Predictive value of ICD-9-CM codes used in vaccine safety research. Methods Inf Med 47 (2008) 328-335
9. Mullooly J.P. Misclassification model for person-time analysis of automated medical care databases. Am J Epidemiol 144 (1996) 782-792
10. Bonhoeffer J., Menkes J., Gold M.S., Souza-Brito G., Fisher M.C., Halsey N., et al. Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 22 (2004) 557-562
11. Destefano F. The Vaccine Safety Datalink project. Pharmacoepidemiol Drug Saf 10 (2001) 403-406
12. Chen R.T., Destefano F., Davis R.L., Jackson L.A., Thompson R.S., Mullooly J.P., et al. The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA. Bull World Health Organ 78 (2000) 186-194
13. Lieu T.A., Kulldorff M., Davis R.L., Lewis E.M., Weintraub E., Yih K., et al. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care 45 (2007) S89-S95
14. Rapid cycle analysis of pentavalent rotavirus vaccine safety in the Vaccine Safety Datalink population. 08 Oct. Presented at the 46th Infectious Disease Society of America annual meeting. Washington, DC (2008)
15. Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. Morb Mortal Wkly Rep 57 (2008) 258-260
16. Influenza vaccine safety: simulating real-time surveillance for adverse events in the Vaccine Safety Datalink project. Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America 46th Annual Meeting. Washington, DC (2008)
17. The Risk of Seizures after Acellular Pertussis Vaccines in Early Childhood-United States, 2002-2006. 2009 EIS Conference (2009)
18. Yih W.K., Nordin J.D., Kulldorff M., Lewis E., Lieu T.A., Shi P., et al. An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using near real-time surveillance for adverse events in the Vaccine Safety Datalink (2009)
19. Hauser W.A. The prevalence and incidence of convulsive disorders in children. Epilepsia 35 Suppl. 2 (1994) S1-S6